Atropine Sulfate Injection 0.5mg/1ml Pharmaceuticals GMP

Name: Atropine Sulfate Injection 0.5mg/1ml Pharmaceuticals GMP
Brand: Shijiazhuang G-House Trading Co., Ltd.
SKU: 1930456742

Hebei, ChinaShijiazhuang G-House Trading Co., Ltd.

US$0.10

3,000 boxes

Sample price:US$0.10/piece.Request sample

Product profile

Customization

Available

Application

Internal Medicine

Usage Mode

For external use

Model NO.

0.5mg/1ml

Suitable for

Elderly, Children, Adult

State

Liquid

Shape

Liquid

Type

Organic Chemicals

Pharmaceutical Technology

Chemical Synthesis

Finished Medicines

Anticholinergic

Transport Package

Carton

Specification

10 ampoules/packet, 10 packets/box(10x10x1ml)

Trademark

Customer brand

Origin

China

HS Code

3004909099

Production Capacity

500000 Boxes/Year

Company profile

Importers and ExportersHigh Repeat Buyers ChoiceYears of Export ExperienceFast Delivery

Shijiazhuang G-House Trading Co., Ltd.

Hebei, China

Business Type: Manufacturer/Factory, Trading CompanyExport Year: 2008-08-13Nearest Port: Xingang, Qingdao, ShanghaiAverage Response Time: ≤6.17hTerms of Payment: LC, T/T, D/P, etc.International Commercial Terms(Incoterms): FOB, CFR, CIF

AI-Powered supplier vetting

SummaryShijiazhuang G-House Trading Co., Ltd. is a Chinese limited trading company primarily engaged in pharmaceuticals. Despite strong export activity and considerable customization capability, the company lacks certain service capabilities and comprehensive after-sales procedures. The firm provides OEM and ODM services but doesn't have a significant R&D focus or SDK availability. Financial data is available for the past three years, but overseas presence is limited.

Supplier typeThe supplier is identified as a limited company with a trading and manufacturing role, focusing on pharmaceuticals.

CertificationsThe supplier was audited by BV, but the result of the evaluation wasn't favorable, as indicated by the audit result '0'.

After-Sales capabilityThere are no written procedures or records for handling corrective actions or customer complaints, indicating a lack of systematic after-sales service capability.

Financial creditFinancial data is recorded for the past three years (2020, 2021, 2022), which suggests a level of financial transparency.

R&D capabilityThe supplier lacks innovation indicators like R&D with SDK availability and hasn't developed new products in the past year.

Production capacityThe supplier offers OEM and ODM services, indicating strong production capabilities in terms of design and manufacturing.

Customization capabilityThere is significant customization capability, with services ranging from minor to full customization.

Client casesThe supplier lacks overseas showrooms, agents, or branches and hasn't participated in offline trade shows, suggesting limited customer engagement globally.